<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="121">
  <!-- This xml conforms to:  http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>Information obtained from ClinicalTrials.gov on October 20, 2011</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01257854</url>
  </required_header>
  <id_info>
    <org_study_id>2009-018105-41</org_study_id>
    <secondary_id>2009-018105-41</secondary_id>
    <nct_id>NCT01257854</nct_id>
  </id_info>
  <brief_title>Polymorphisms and Busulfan PK Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Pediatric Oncology Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Group for Blood and Marrow Transplantation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Pediatric Oncology Group</source>
  <oversight_info>
    <authority>Switzerland: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Test the correlations between the pharmacogenetic and pharmacokinetic of Busulfan IV in
      children receiving hematopoietic stem cell transplantation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Most of the drugs used to treat cancer are metabolised by hepatic enzymes such as cytochrome
      P450 or Glutathion-S-Transferase (GST). These enzymatic pathways can be more or less active
      in the drug's metabolism according to the given polymorphism of each patient
      (pharmacogenomics).

      The current hypothesis is that some functional polymorphisms of genes, which control
      important enzymes in Busulfan metabolism, contribute to the observed interindividual
      variability in PK of this drug. This variability can hence predict the resistance as well as
      the toxicity from a drug in patients who have cancer. The pharmacokinetic profile of
      different drugs, which have a hepatic metabolism, can be dramatically modified by these
      polymorphisms. Busulfan is a major drug used in the conditioning regimen before
      hematopoietic stem cell transplantation, particularly in children in whom total body
      irradiation has to be avoided. This drug has a narrow therapeutic index. At a lower systemic
      exposure than the targeted one, Busulfan has insufficient activity and hence an increased
      risk of transplant rejection and leukemic relapse.

      At higher systemic exposures, the toxicity risk increases dramatically with an elevated
      incidence of hepatic veno-occlusive disease (VOD). Pharmacokinetic monitoring of Busulfan
      allows optimal dosing. The recommended doses are based on the weight, body surface area or
      age. Nevertheless, a majority of patients will still need an adjustment of the dose
      administered after their first dose: this will result in a cumulative systemic exposure that
      will be over or under therapeutic. Busulfan is metabolised principally by the GSTA1, as well
      as by other GST enzymes like the GSTM1 and GSTP1. These enzymes are present in the liver as
      well as in the intestinal cells and are up regulated in the digestive system of young
      children.With this study we will look for the polymorphism in GST genes, look at the
      Busulfan IV parmacokinetics and finally look at the GST alpha enzyme activity and see if
      there is a correlation with clinical end points. This study will also allow to do some DNA
      banking for future studies in genetics. This multi centric study is sponsor by the Swiss
      pediatric Oncology Group and is a Europen Bone and Marrow Transplantation study onpen in  6
      countries (Switzerland, Canada, Italy, Holland, Tscèque republic, ).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2008</start_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model:  Cohort</study_design>
  <primary_outcome>
    <measure>polymorphisms  in genes involved in Busulfan pathways correlation with pharmacokinetic</measure>
    <time_frame>1 year post hematopoietic stem cell transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>polymorphisms  in genes involved in Busulfan pathways correlation with toxicity</measure>
    <time_frame>1 year post hematopoietic stem cell transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>polymorphisms  in genes involved in Busulfan pathways correlation with survival</measure>
    <time_frame>1 year post stem cell transplantation</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Any Disease in Children Who Receive a Stem Cell Transplantation With Busulfan IV</condition>
  <arm_group>
    <arm_group_label>Busulfan, pharmacogenetic, pharmacokinetic, children</arm_group_label>
    <description>Children who recieve Busulfan IV in the conditioning regimen before stem cell transplantation and have a pharmacokinetic of busulfan</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA  from each patient are kept. Plasma from some centers are kept
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        primary care clinic of pediatric
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must be ≤ than 18 years of age at study entry on this protocol

          -  The patient must receive iv Busulfan as part of his hematopoietic stem cell
             transplant conditioning regimen.

          -  Each participating center has to go through a PK cross validation

          -  All patients (or their legal guardians) must sign a document of informed   consent
             that has been approved by the Institutional Human Review Committee.

          -  Each center has to do his own PK of BU
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ansari Marc, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hopital CAntonal de Genève, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ansari Marc, MD</last_name>
    <phone>+41223824589</phone>
    <email>marc.ansari@hcuge.ch</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Duval Michel, MD</last_name>
    <email>michel.duval@umontreal.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>ON M5G 1X8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Chu St Justine</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansari Marc, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Duval Michel, MD</last_name>
    </contact_backup>
    <investigator>
      <last_name>Ansari Marc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alberta children's hospital</name>
      <address>
        <city>Alberta</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lewis victor, MD</last_name>
    </contact>
    <investigator>
      <last_name>lewis victor, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles University Motol Prague</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sedlacek Petr, MD</last_name>
      <email>Petr.Sedlacek@fnmotol.cz</email>
    </contact>
    <investigator>
      <last_name>Sedlacek Petr, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>San Raffaele Hospital</name>
      <address>
        <city>San Raffaele</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ume Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hopital Cantonal de Genève</name>
      <address>
        <city>Geneva</city>
        <zip>1206</zip>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ansari Marc, MD</last_name>
      <phone>+41223824589</phone>
      <email>marc.ansari@hcuge.ch</email>
    </contact>
    <contact_backup>
      <last_name>Ozsahin Hulya, MD</last_name>
      <email>Ayse.H.Ozsahin@hcuge.ch</email>
    </contact_backup>
    <investigator>
      <last_name>Ansari Marc, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Krajinovic Maja</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czech Republic</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>Switzerland</country>
  </location_countries>
  <link>
    <url>http://www.ebmt.org/5WorkingParties/PDWP/wparties-pd3.html#pros</url>
    <description>http://www.ebmt.org/5WorkingParties/PDWP/</description>
  </link>
  <reference>
    <citation>Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Théoret Y, Champagne MA, Krajinovic M. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant. 2010 Feb;45(2):261-7. Epub 2009 Jul 6.</citation>
    <PMID>19584821</PMID>
  </reference>
  <reference>
    <citation>Ansari M, Krajinovic M. Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics. 2009 Nov;10(11):1729-32. No abstract available.</citation>
    <PMID>19891548</PMID>
  </reference>
  <verification_date>December 2010</verification_date>
  <lastchanged_date>December 8, 2010</lastchanged_date>
  <firstreceived_date>December 8, 2010</firstreceived_date>
  <responsible_party>
    <name_title>Nicolas von der Weid/SPOG president</name_title>
    <organization>SPOG</organization>
  </responsible_party>
  <keyword>busulfan</keyword>
  <keyword>pharmacogenetic</keyword>
  <keyword>pharmacokinetic</keyword>
  <keyword>toxicity</keyword>
  <keyword>survival</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
</clinical_study>
